| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 327 | 5.078 | 17.267 | 16.448 | 22.574 | 5.392 | 37.243 | 34.844 | 19.459 | 15.027 |
| Total Income - EUR | 435 | 38.546 | 20.796 | 22.967 | 40.914 | 21.048 | 49.663 | 41.501 | 22.492 | 20.893 |
| Total Expenses - EUR | 720 | 12.214 | 18.465 | 22.801 | 21.941 | 19.635 | 47.138 | 25.182 | 20.205 | 19.839 |
| Gross Profit/Loss - EUR | -285 | 26.332 | 2.331 | 166 | 18.973 | 1.413 | 2.524 | 16.319 | 2.287 | 1.055 |
| Net Profit/Loss - EUR | -295 | 26.066 | 1.827 | -266 | 18.282 | 1.113 | 2.177 | 15.321 | 2.109 | 1.055 |
| Employees | 0 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
Check the financial reports for the company - Bioelymar Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 8.079 | 24.397 | 19.679 | 21.169 | 28.766 | 23.489 | 32.790 | 28.214 | 20.219 | 16.669 |
| Current Assets | 434 | 10.485 | 54.322 | 52.323 | 36.475 | 33.317 | 35.682 | 59.721 | 95.552 | 52.018 |
| Inventories | 0 | 2.432 | 0 | 2.529 | 252 | 366 | 733 | 862 | 12.421 | 12.910 |
| Receivables | 0 | 3.087 | 3.567 | 11.667 | 3.430 | 5.129 | 11.113 | 44.463 | 69.416 | 34.718 |
| Cash | 434 | 4.965 | 50.755 | 38.126 | 32.793 | 27.822 | 23.836 | 14.395 | 13.715 | 4.390 |
| Shareholders Funds | -295 | 25.818 | 27.208 | 26.443 | 19.822 | 20.560 | 22.281 | 42.923 | 44.901 | 45.705 |
| Social Capital | 0 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 8.808 | 9.063 | 5.680 | 6.690 | 20.353 | 19.421 | 37.332 | 36.126 | 62.011 | 14.172 |
| Income in Advance | 0 | 0 | 41.113 | 40.359 | 25.066 | 16.825 | 8.859 | 8.886 | 8.859 | 8.810 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "111 - 111" | |||||||||
| CAEN Financial Year |
111
|
|||||||||
Comments - Bioelymar Srl